Figure 3.
Plot of potential power for three different effect sizes for each of the measures investigated based on the 1-year study design described in the text. Note that the ALSFRS-R and MVICT megascore values virtually overlie one another. *Data derived from celecoxib in ALS study (Cudkowicz et al, 2006).